Form 4: Director Parsons Exercises DMAC Stock Options

DiaMedica Therapeutics Director James T. Parsons exercised 12,000 stock options, increasing his direct beneficial ownership to 87,854 common shares.

Summary

• James T. Parsons, a Director of DiaMedica Therapeutics Inc. (DMAC), reported an insider transaction on November 21, 2025.
• Parsons exercised 12,000 stock options at an exercise price of $2.2 per share.
• The exercise price was converted from CAD$ to US$ on the transaction date.
• Following this transaction, Parsons directly beneficially owns 87,854 shares of DiaMedica Therapeutics Inc. Common Stock.
• The stock options were fully vested and had an expiration date of December 1, 2025.

Sentiment

Score: 6

Explanation: The exercise of stock options by a director is generally a neutral to slightly positive signal, indicating continued engagement and potential confidence in the company's long-term prospects, but it's a routine event and not indicative of significant new developments.

Positives

• A director increased their direct ownership in the company by exercising stock options, which can signal confidence in the company's future prospects.

Future Outlook

This Form 4 filing is a report of an insider transaction and does not contain forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This is a routine insider transaction report for a director exercising stock options, a common event across all industries for executive and board compensation. It does not provide specific industry-wide context or trends.

Related Party Transactions

• The exercise of stock options by Director James T. Parsons is a transaction between the company and a related party (an insider) as part of a compensation plan.

Stakeholder Impact

• Shareholders: Increased insider ownership may be viewed as a minor positive signal, suggesting alignment of interests between management and shareholders.

Key Dates

Recommendation

The filing reports a routine exercise of stock options by a director, which increases their direct ownership. While this can be a minor positive signal of confidence, it does not provide sufficient new information to change an investment thesis or warrant a strong buy or sell recommendation. It's a standard insider transaction that typically has limited impact on short-term share price.

Keywords

DiaMedica Therapeutics, DMAC, Form 4, Insider Transaction, Stock Options, Director, Beneficial Ownership, James T. Parsons, Equity